Bolt Biotherapeutics, Inc. BOLT · SEC Filings

website

Bolt Biotherapeutics, Inc. is a biotechnology company currently conducting clinical trials, focused ...

Price6.43

Market Cap15.75 M

Float1.96 M

CountryUS

SectorHealthcare

ExchangeNASDAQ

Overview Filings Insights Dilution News Transcripts

Search in Documents

Open in Studio Login

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

Financials

TYPE

HEADLINE

FILED AT

News

TYPE

HEADLINE

FILED AT

Prospectus

TYPE

HEADLINE

FILED AT

424B5

ATM | Offering amount: $75,000,000

Apr 7, 2022

424B4

11,500,000 Shares-

Feb 5, 2021

Registrations

TYPE

HEADLINE

FILED AT

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 28, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 28, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 25, 2025

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Apr 15, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 15, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

May 20, 2024

Ownerships

TYPE

HEADLINE

FILED AT

Coastlands Capital LP (Reporting)

Nov 6, 2026

SCHEDULE 13G

Coastlands Capital LP (Filed by)

Nov 6, 2026

GUJRATHI SHEILA (Reporting)

Oct 27, 2026

GUJRATHI SHEILA (Reporting)

Oct 27, 2026

Yonehiro Grant (Reporting)

Sep 21, 2026

Nemec Sarah (Reporting)

Sep 21, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Apr 8, 2022

LETTER

Form UPLOAD - SEC-generated letter

Apr 6, 2022

CORRESP

Form CORRESP - Correspondence

Apr 5, 2022

EFFECT

Form EFFECT - Notice of Effectiveness

Feb 5, 2021

CORRESP

Form CORRESP - Correspondence

Feb 2, 2021

CORRESP

Form CORRESP - Correspondence

Feb 2, 2021